Pfizer-BioNTech Vaccine’s Cold Storage Needs Complicate Logistics Of Transportation, Delivery, Especially In Remote Asian, African Regions
The Guardian: Pfizer and BioNTech’s vaccine poses global logistics challenge
“Two vast football-pitch-sized facilities equipped with hundreds of large freezers in Kalamazoo, Michigan, and Puurs, Belgium, will be the centers of the huge effort to ship the coronavirus vaccine, developed by U.S. drug giant Pfizer and German biotech firm BioNTech, around the world. Governments are scrambling to prepare for the rollout of the vaccine, which must be stored at -70C (-94F), after the announcement from the two companies that it was more than 90% effective and had no serious side-effects. The news sparked hopes of a return to normal life and a stock market rally, but now minds are turning to the practicalities of getting the vaccine quickly to populations across the world, in particular to the vulnerable people who need it most…” (Kollewe, 11/10)
Reuters: Pfizer COVID-19 vaccine ‘very promising’ but cold chain issues: WHO
“…However, the necessity to keep the vaccine in extremely cold storage could complicate any inoculation program, above all in regions of Asia or Africa where the climate is warm, distances vast, and the required infrastructure may be lacking…” (Nebehay, 11/10).
Reuters: Swiss plan for centers to deliver deep-chilled COVID vaccine
“…Switzerland, whose neighbor Germany has already said it is planning centralized inoculation centers, on Tuesday reported nearly 6,000 new coronavirus infections and 107 new deaths. The Swiss have reserved nearly 10 million doses of vaccine candidates that both AstraZeneca and Moderna are developing, should they pass trials…” (Miller et al., 11/10).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.